-
Je něco špatně v tomto záznamu ?
An up-to-date catalogue of urinary markers for the management of prostate cancer
S. Brönimann, B. Pradere, P. Karakiewicz, NA. Huebner, A. Briganti, SF. Shariat,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- analýza moči metody trendy MeSH
- antigeny nádorové moč MeSH
- biopsie MeSH
- lidé MeSH
- nádorové biomarkery moč MeSH
- nádory prostaty diagnóza moč MeSH
- prostata diagnostické zobrazování MeSH
- prostatický specifický antigen MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE OF REVIEW: Prostate cancer (PCa) is the most commonly diagnosed cancer in men. Poor specificity and sensitivity of total PSA often results in over and sometimes underdetection/treatment. Therefore, more specific and sensitive biomarkers for the detection and monitoring especially of clinically significant PCa as well as treatment-specific markers are much sought after. In this field, urine has emerged as a promising noninvasive source of biomarkers. RECENT FINDINGS: RNA-based biomarkers are the most extensively studied type of urinary nucleic acids. ERG-Score/MiPS (Mi-Prostate Score) and SelectMDx might be considered as additional parameters together with clinical and imaging modalities to decrease unnecessary biopsies. miR Sentinel Tests could make it possible to accurately detect the presence of cancer and to distinguish low-grade from high-grade disease. In men with previous negative biopsies, PCA3 may suggest the need to repeat biopsy. SUMMARY: The definitive role of these markers and their clinical benefit needs future validation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027875
- 003
- CZ-PrNML
- 005
- 20210114152531.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000807 $2 doi
- 035 __
- $a (PubMed)32701725
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brönimann, Stephan $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 245 13
- $a An up-to-date catalogue of urinary markers for the management of prostate cancer / $c S. Brönimann, B. Pradere, P. Karakiewicz, NA. Huebner, A. Briganti, SF. Shariat,
- 520 9_
- $a PURPOSE OF REVIEW: Prostate cancer (PCa) is the most commonly diagnosed cancer in men. Poor specificity and sensitivity of total PSA often results in over and sometimes underdetection/treatment. Therefore, more specific and sensitive biomarkers for the detection and monitoring especially of clinically significant PCa as well as treatment-specific markers are much sought after. In this field, urine has emerged as a promising noninvasive source of biomarkers. RECENT FINDINGS: RNA-based biomarkers are the most extensively studied type of urinary nucleic acids. ERG-Score/MiPS (Mi-Prostate Score) and SelectMDx might be considered as additional parameters together with clinical and imaging modalities to decrease unnecessary biopsies. miR Sentinel Tests could make it possible to accurately detect the presence of cancer and to distinguish low-grade from high-grade disease. In men with previous negative biopsies, PCA3 may suggest the need to repeat biopsy. SUMMARY: The definitive role of these markers and their clinical benefit needs future validation.
- 650 _2
- $a antigeny nádorové $x moč $7 D000951
- 650 _2
- $a nádorové biomarkery $x moč $7 D014408
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prostata $x diagnostické zobrazování $7 D011467
- 650 _2
- $a prostatický specifický antigen $7 D017430
- 650 _2
- $a nádory prostaty $x diagnóza $x moč $7 D011471
- 650 _2
- $a analýza moči $x metody $x trendy $7 D016482
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.
- 700 1_
- $a Karakiewicz, Pierre $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
- 700 1_
- $a Huebner, Nicolai A $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Division of Urology, Department of Special Surgery, Jordan University Hospital, The 2 University of Jordan, Amman, Jordan. Departments of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. European Association of Urology research foundation, Arnhem, the Netherlands. Karl Landsteiner Institute of Urology and Andrology, Vienna.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 5 (2020), s. 684-688
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32701725 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152529 $b ABA008
- 999 __
- $a ok $b bmc $g 1608210 $s 1119055
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 5 $d 684-688 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20210105
